Research graph
References from Managing skin-related adverse events during mirdametinib treatment for NF1-PNs: expert guidance from the ReNeu trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression
10.1146/annurev-pathol-011811-132441 · 2012 · External reference
Management of neurofibromatosis type 1-associated plexiform neurofibromas
10.1093/neuonc/noac146 · 2022 · External reference
Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1
10.1016/j.jpeds.2011.08.051 · 2012 · External reference
Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis
10.1186/s13023-023-02911-2 · 2023 · External reference
Health supervision for children with neurofibromatosis type 1
10.1542/peds.2019-0660 · 2019 · External reference
Neurofibromatosis type 1
10.1038/nrdp.2017.4 · 2017 · External reference
Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review
10.1016/j.esmoop.2021.100223 · 2021 · External reference
GOMEKLI® (mirdametinib) [prescribing information]
2025 · External reference
Efficacy and safety of trametinib in neurofibromatosis type 1-associated plexiform neurofibroma and low-grade glioma: a systematic review and meta-analysis
10.3390/ph15080956 · 2022 · External reference
KOSELUGO® (selumetinib) capsules; for oral use. KOSELUGO® (selumetinib) oral granules [prescribing information]
2025 · External reference
MEK inhibitor binimetinib shows clinical activity in children with neurofibromatosis type 1- associated plexiform neurofibromas: a report from Pnoc and the Nf Clinical Trials Consortium [abstract]
10.1093/neuonc/noaa222.619 · 2020 · External reference
Binimetinib leads to radiographic response in adults with neurofibromatosis type 1 associated plexiform neurofibromas: a report from the NFCTC and PNOC [abstract]
2021 · External reference
Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas
10.1056/nejmoa1605943 · 2016 · External reference
SPRINT: phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
10.1200/jco.2018.36.15_suppl.10503 · 2018 · External reference
NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas
10.1200/jco.20.02220 · 2021 · External reference
Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: a phase I/IIa study [abstract]
10.1200/jco.2018.36.15_suppl.10504 · 2018 · External reference
ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma
10.1200/jco.24.01034 · 2025 · External reference
The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors
10.1002/ijc.31052 · 2018 · External reference
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1
10.1002/pbc.25546 · 2015 · External reference
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers
10.1158/1078-0432.ccr-09-1883 · 2010 · External reference
The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities
10.1634/theoncologist.2020-0069 · 2020 · External reference
Cutaneous side effects of targeted therapy and immunotherapy for advanced melanoma
10.1155/2018/5036213 · 2018 · External reference
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
10.1177/1758834014566428 · 2015 · External reference
Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: a multicenter study
10.1016/j.jaad.2020.07.044 · 2021 · External reference
Adverse cutaneous reactions associated with MEK inhibitor therapy in a pediatric population
10.1016/j.jaad.2023.06.052 · 2023 · External reference
Cutaneous reactions in children treated with the mitogen-activated protein kinase extracellular signal-regulated kinase inhibitor trametinib for neural tumors
10.1111/pde.13038 · 2017 · External reference
Selumetinib in children with inoperable plexiform neurofibromas
10.1056/nejmoa1912735 · 2020 · External reference
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas
10.1093/neuonc/noad086 · 2023 · External reference
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial
10.1038/s41591-024-03361-4 · 2025 · External reference
Cutaneous toxicities of MEK inhibitor use in children: a comparison of binimetinib and selumetinib
10.1111/pde.15792 · 2025 · External reference
Cutaneous adverse events to targeted therapies and immuno-therapies in children: a retrospective study of 103 patients from two tertiary haemato-oncology referral centres
10.2340/00015555-3867 · 2021 · External reference
Cutaneous reactions in pediatric patients treated with MEK inhibitors: a retrospective single-center study
10.1159/000539374 · 2024 · External reference
Cutaneous reactions to targeted therapies in children with CNS tumors: a cross-sectional study
10.1002/pbc.27682 · 2019 · External reference
Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic
10.1007/s40257-013-0021-0 · 2013 · External reference
Common terminology criteria for adverse events (CTCAE) v5.0
10.32388/erjxiq · 2018 · External reference
GOMEKLITM (mirdametinib) tablets for oral suspension [prescribing information]
2025 · External reference
MAPK pathway involved in epidermal terminal differentiation of normal human epidermal keratinocytes
10.1515/med-2018-0029 · 2018 · External reference
When bugs and drugs conspire: driving acneiform skin toxicity
10.1172/jci133787 · 2020 · External reference
IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
10.1172/jci128678 · 2020 · External reference
Cancer therapy-induced dermatotoxicity as a window to understanding skin immunity
10.1016/j.hoc.2024.05.002 · 2024 · External reference
MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus
10.1093/neuonc/noac165 · 2022 · External reference
Addressing skin adverse events during mirdametinib treatment in patients with neurofibromatosis type 1-associated plexiform neurofibromas: Guidance from a multidisciplinary group of experts involved in the ReNeu trial
External reference
Mechanisms of cutaneous toxicities to EGFR inhibitors
10.1038/nrc1970 · 2006 · External reference
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
10.1111/j.1468-3083.2012.04546.x · 2013 · External reference
Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
10.1016/j.annonc.2020.11.005 · 2021 · External reference
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
10.1016/s1470-2045(17)30180-8 · 2017 · External reference
Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib
10.1111/ajd.12124 · 2014 · External reference
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
10.1007/s10637-010-9567-3 · 2011 · External reference
Dermatologic effects of selumetinib in pediatric patients with neurofibromatosis type 1: clinical challenges and therapeutic management
10.3390/jcm13061792 · 2024 · External reference
Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails
10.1007/s40257-018-0384-3 · 2018 · External reference
Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors
10.1001/archderm.138.1.129 · 2002 · External reference
The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
10.5114/ada.2017.71106 · 2017 · External reference
Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review
10.1111/jocd.15704 · 2023 · External reference
Bleach for atopic dermatitis
10.1097/der.0000000000000358 · 2018 · External reference
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations
10.1016/j.anai.2023.11.009 · 2024 · External reference
Acneiform eruptions
2024 · External reference
Treatment of trametinib-associated folliculitis eruption with fluconazole
10.1001/jamadermatol.2020.0284 · 2020 · External reference
Minocycline for acne vulgaris: efficacy and safety
10.1002/14651858.cd002086.pub2 · 2012 · External reference
Prevention and management of acneiform rash associated with EGFR inhibitor therapy: a systematic review and meta-analysis
10.1111/ajco.13740 · 2022 · External reference
Doxycycline hyclate delayed-release tablets, for oral use [prescribing information]
2016 · External reference
Topical corticosteroids: choice and application
2021 · External reference
Asteatotic eczema
2024 · External reference
Management of adverse events in patients with pediatric low-grade glioma treated with MAPK-directed therapies: Delphi consensus recommendations and unmet needs
10.1093/nop/npag006 · 2026 · External reference
Management of dermatological adverse events associated with MEK inhibitors
10.1016/j.ad.2026.104664 · 2026 · External reference
Doxycycline prophylaxis in adolescent patients treated with MEK inhibitors
10.1111/pde.15996 · 2025 · External reference
Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN) [abstract]
10.1200/jco.2018.36.15_suppl.10537 · 2018 · External reference
Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors
10.1001/archderm.138.1.129 · ExternalCitation · doi-reference
Treatment of trametinib-associated folliculitis eruption with fluconazole
10.1001/jamadermatol.2020.0284 · ExternalCitation · doi-reference
Minocycline for acne vulgaris: efficacy and safety
10.1002/14651858.cd002086.pub2 · ExternalCitation · doi-reference
The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors
10.1002/ijc.31052 · ExternalCitation · doi-reference
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1
10.1002/pbc.25546 · ExternalCitation · doi-reference
Cutaneous reactions to targeted therapies in children with CNS tumors: a cross-sectional study
10.1002/pbc.27682 · ExternalCitation · doi-reference
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
10.1007/s10637-010-9567-3 · ExternalCitation · doi-reference
Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic
10.1007/s40257-013-0021-0 · ExternalCitation · doi-reference
Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails
10.1007/s40257-018-0384-3 · ExternalCitation · doi-reference
Management of dermatological adverse events associated with MEK inhibitors
10.1016/j.ad.2026.104664 · ExternalCitation · doi-reference
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations
10.1016/j.anai.2023.11.009 · ExternalCitation · doi-reference
Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
10.1016/j.annonc.2020.11.005 · ExternalCitation · doi-reference
Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review
10.1016/j.esmoop.2021.100223 · ExternalCitation · doi-reference
Cancer therapy-induced dermatotoxicity as a window to understanding skin immunity
10.1016/j.hoc.2024.05.002 · ExternalCitation · doi-reference
Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: a multicenter study
10.1016/j.jaad.2020.07.044 · ExternalCitation · doi-reference
Adverse cutaneous reactions associated with MEK inhibitor therapy in a pediatric population
10.1016/j.jaad.2023.06.052 · ExternalCitation · doi-reference
Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1
10.1016/j.jpeds.2011.08.051 · ExternalCitation · doi-reference
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
10.1016/s1470-2045(17)30180-8 · ExternalCitation · doi-reference
Mechanisms of cutaneous toxicities to EGFR inhibitors
10.1038/nrc1970 · ExternalCitation · doi-reference
Neurofibromatosis type 1
10.1038/nrdp.2017.4 · ExternalCitation · doi-reference
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial
10.1038/s41591-024-03361-4 · ExternalCitation · doi-reference
Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas
10.1056/nejmoa1605943 · ExternalCitation · doi-reference
Selumetinib in children with inoperable plexiform neurofibromas
10.1056/nejmoa1912735 · ExternalCitation · doi-reference
MEK inhibitor binimetinib shows clinical activity in children with neurofibromatosis type 1- associated plexiform neurofibromas: a report from Pnoc and the Nf Clinical Trials Consortium [abstract]
10.1093/neuonc/noaa222.619 · ExternalCitation · doi-reference
Management of neurofibromatosis type 1-associated plexiform neurofibromas
10.1093/neuonc/noac146 · ExternalCitation · doi-reference
MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus
10.1093/neuonc/noac165 · ExternalCitation · doi-reference
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas
10.1093/neuonc/noad086 · ExternalCitation · doi-reference
Management of adverse events in patients with pediatric low-grade glioma treated with MAPK-directed therapies: Delphi consensus recommendations and unmet needs
10.1093/nop/npag006 · ExternalCitation · doi-reference
Bleach for atopic dermatitis
10.1097/der.0000000000000358 · ExternalCitation · doi-reference
Prevention and management of acneiform rash associated with EGFR inhibitor therapy: a systematic review and meta-analysis
10.1111/ajco.13740 · ExternalCitation · doi-reference
Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib
10.1111/ajd.12124 · ExternalCitation · doi-reference
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
10.1111/j.1468-3083.2012.04546.x · ExternalCitation · doi-reference
Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review
10.1111/jocd.15704 · ExternalCitation · doi-reference
Cutaneous reactions in children treated with the mitogen-activated protein kinase extracellular signal-regulated kinase inhibitor trametinib for neural tumors
10.1111/pde.13038 · ExternalCitation · doi-reference
Cutaneous toxicities of MEK inhibitor use in children: a comparison of binimetinib and selumetinib
10.1111/pde.15792 · ExternalCitation · doi-reference
Doxycycline prophylaxis in adolescent patients treated with MEK inhibitors
10.1111/pde.15996 · ExternalCitation · doi-reference
Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression
10.1146/annurev-pathol-011811-132441 · ExternalCitation · doi-reference
Cutaneous side effects of targeted therapy and immunotherapy for advanced melanoma
10.1155/2018/5036213 · ExternalCitation · doi-reference
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers
10.1158/1078-0432.ccr-09-1883 · ExternalCitation · doi-reference
Cutaneous reactions in pediatric patients treated with MEK inhibitors: a retrospective single-center study
10.1159/000539374 · ExternalCitation · doi-reference
IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
10.1172/jci128678 · ExternalCitation · doi-reference
When bugs and drugs conspire: driving acneiform skin toxicity
10.1172/jci133787 · ExternalCitation · doi-reference
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
10.1177/1758834014566428 · ExternalCitation · doi-reference
Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis
10.1186/s13023-023-02911-2 · ExternalCitation · doi-reference
NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas
10.1200/jco.20.02220 · ExternalCitation · doi-reference
SPRINT: phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
10.1200/jco.2018.36.15_suppl.10503 · ExternalCitation · doi-reference
Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: a phase I/IIa study [abstract]
10.1200/jco.2018.36.15_suppl.10504 · ExternalCitation · doi-reference
Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN) [abstract]
10.1200/jco.2018.36.15_suppl.10537 · ExternalCitation · doi-reference
ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma
10.1200/jco.24.01034 · ExternalCitation · doi-reference
MAPK pathway involved in epidermal terminal differentiation of normal human epidermal keratinocytes
10.1515/med-2018-0029 · ExternalCitation · doi-reference
Health supervision for children with neurofibromatosis type 1
10.1542/peds.2019-0660 · ExternalCitation · doi-reference
The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities
10.1634/theoncologist.2020-0069 · ExternalCitation · doi-reference
Cutaneous adverse events to targeted therapies and immuno-therapies in children: a retrospective study of 103 patients from two tertiary haemato-oncology referral centres
10.2340/00015555-3867 · ExternalCitation · doi-reference
Common terminology criteria for adverse events (CTCAE) v5.0
10.32388/erjxiq · ExternalCitation · doi-reference
Dermatologic effects of selumetinib in pediatric patients with neurofibromatosis type 1: clinical challenges and therapeutic management
10.3390/jcm13061792 · ExternalCitation · doi-reference
Efficacy and safety of trametinib in neurofibromatosis type 1-associated plexiform neurofibroma and low-grade glioma: a systematic review and meta-analysis
10.3390/ph15080956 · ExternalCitation · doi-reference
The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
10.5114/ada.2017.71106 · ExternalCitation · doi-reference
